Author

Matt Marton

Observed name: M. Marton

Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

Observed institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

OpenAlex ID: A5000371599

Abstract CT229: Olaparib in patients (pts) with previously treated, homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD)-positive advanced cancer: Phase II LYNK-002 study

2019 · David Hyman, Andrew Hendifar, et al. · Cancer Research · 2

261 Association of T-cell–inflamed gene expression profile and PD-L1 status with efficacy of pembrolizumab in patients with esophageal cancer from KEYNOTE-180

2020 · Manish Shah, Takashi Kojima, et al. · Journal for ImmunoTherapy of Cancer · 1

978 Concordance of the FDA-approved companion diagnostic and a next-generation sequencing assay kit for assessing homologous recombination deficiency in ovarian cancer

2021 · W. Weichert, P. Qiu, et al. · International Journal of Gynecological Cancer

Abstract CT229: Olaparib in patients (pts) with previously treated, homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD)-positive advanced cancer: Phase II LYNK-002 study

2019 · David Hyman, Andrew Hendifar, et al. · Clinical Trials

Works count: 4

Citation count: 3

H-index: 1

I10-index: